Information
BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The
Original sourceAI Summary
Haemonetics Corporation is set to release its third quarter fiscal year 2026 results on February 5, 2026, followed by a conference call at 8:00 am ET. The results will be available for a year through a replay, underlining the company's commitment to transparency and communication with investors.
Trading Thesis
Anticipated financial results may positively influence HAE stock performance.
Market-Moving
- Positive earnings could boost investor confidence in HAE.
- Decrease in earnings might lead to negative market reactions.
- Strong guidance could enhance stock performance leading up to February 5.
- Market volatility may arise around the earnings release date.
- Analysts' expectations will play a crucial role in stock movement.
Key Facts
- Q3 FY2026 results will be released at 6:00 am ET.
- Conference call scheduled for February 5, 2026, at 8:00 am ET.
- Live webcast available for investors and analysts.
- Replay of the conference call will be accessible for one year.
Companies Mentioned
- Haemonetics Corporation (HAE): Key player in medical technology, enhancing quality and efficiency of health care.
Earnings
This event falls under earnings announcements, which typically drive stock volatility based on performance expectations. Investor sentiment will heavily depend on the results and management commentary during the conference call.
FAQ
Why Bullish?
Anticipated positive earnings could reinforce market confidence in Haemonetics, as demonstrated by past performance increases after favorable earnings reports.
How important is it?
Earnings reports are critical for stock evaluation; thus, anticipation of results and market reaction creates significant relevance for HAE.
Why Short Term?
The impact will be most pronounced around the earnings release date, influencing stock movement in the immediate aftermath, akin to previous quarterly releases.
BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 5, 2026.
The call can be accessed via teleconference at: Q3 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/uz42wd2z
A replay of the conference call and webcast will be available for one year beginning on February 5, 2026 at 11:00 am ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Sr. Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-third-quarter-fiscal-year-2026-results-february-5-2026-302655773.html
SOURCE Haemonetics Corporation